Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;12(5):2161-2171.
doi: 10.21037/jtd.2020.04.37.

Sub-solid lung adenocarcinoma in Asian versus Caucasian patients: different biology but similar outcomes

Natalie S Lui  1 , Jalen Benson  1 , Hao He  1 , Bartlomiej R Imielski  1   2 , Christian A Kunder  3 , Douglas Z Liou  1 , Leah M Backhus  1 , Mark F Berry  1 , Joseph B Shrager  1
Affiliations

Sub-solid lung adenocarcinoma in Asian versus Caucasian patients: different biology but similar outcomes

Natalie S Lui et al. J Thorac Dis. 2020 May.

Abstract

Background: Asian and Caucasian patients with lung cancer have been compared in several database studies, with conflicting findings regarding survival. However, these studies did not include proportion of ground-glass opacity or mutational status in their analyses. Asian patients commonly develop sub-solid lung adenocarcinomas that harbor EGFR mutations, which have a better prognosis. We hypothesized that among patients undergoing surgery for sub-solid lung adenocarcinomas, Asian patients have better survival compared to Caucasian patients.

Methods: We identified Asian and Caucasian patients who underwent surgical resection for a sub-solid lung adenocarcinoma from 2002 to 2015 at our institution. Sub-solid was defined as ≥10% ground-glass opacity on preoperative CT scan or ≥10% lepidic component on surgical pathology. Time-to-event multivariable analysis was performed to determine which characteristics were associated with recurrence and survival.

Results: Two hundred twenty-four patients were included with median follow up 48 months. Asian patients were more likely to be never smokers (76.3% vs. 29.0%, P<0.01) and have an EGFR mutation (69.4% vs. 25.6% of those tested, P<0.01), while Caucasian patients were more likely to have a KRAS mutation (23.5% vs. 4.9% of those tested, P<0.01). There was a trend towards Asian patients having a higher proportion of ground-glass opacity (38.8% vs. 30.5%, P=0.11). Time-to-event multivariable analysis showed that higher proportion of ground-glass opacity was significantly associated with better recurrence-free survival (HR 0.76 per 20% increase, P=0.02). However, mutational status and race did not have a significant impact on recurrence-free or overall survival.

Conclusions: Asian and Caucasian patients with sub-solid lung adenocarcinoma have different tumor biology, but recurrence-free and overall survival after surgical resection is similar.

Keywords: Lung adenocarcinoma; ground-glass opacity; sub-solid lung nodule.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.04.37). JBS reports grants and personal fees from Becton-Dickinson, outside the submitted work; In addition, JBS has a patent CRISPR/Cas-mediated Genome Editing to Treat EGFR-mutant Lung Cancer issued. NSL reports other from Auspex, outside the submitted work and serves as an unpaid editorial board member of Journal of Thoracic Disease from Sep 2019 to Aug 2021. MFB serves as an unpaid editorial board member of Journal of Thoracic Disease from Sep 2018 to Aug 2020. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Consort diagram outlining patient selection.
Figure 2
Figure 2
Kaplan-Meier curves for recurrence-free survival by (A) race and (B) EGFR mutation status.
Figure 3
Figure 3
Kaplan-Meier curves for overall survival by (A) race and (B) EGFR mutation status.
See this image and copyright information in PMC

References

    1. Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 2018;124:2785-800. 10.1002/cncr.31551 - DOI - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e1S-e29S. - PMC - PubMed
    1. Ou SH, Zell JA, Ziogas A, et al. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007;110:1532-41. 10.1002/cncr.22938 - DOI - PubMed
    1. Zell JA, Ou SH, Ziogas A, et al. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer 2008;112:136-43. 10.1002/cncr.23146 - DOI - PubMed